Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Oral microbiota
Hospital Authority, Hong Kong
Dry Eye Syndrome
1 trial -
Oral supplementation of vitamin D
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obesity
1 trial -
Orthica Soft Multi Mini and Orthica Fish EPA Mini
Atrium Therapeutics
Psychiatric Hospitalization
1 trial -
Oxytocin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Social Behavior
1 trial -
Oxytocin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Postpartum Hemorrhage
1 trial -
Oxytocin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Mental Health Wellness 1
1 trial -
PCSK9 inhibitor
The First People's Hospital of Lianyungang
Intracranial Artery Stenosis
1 trial -
PCSK9 inhibitor (PCSK9i)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
PD1-BCMA-CART
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
PEG-rhG-CSF
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
PG102P
Hospital Authority, Hong Kong
Uremic Pruritus
1 trial -
PGS 2.0
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Recurrent Pregnancy Loss
1 trial -
PIMS screening
The First People's Hospital of Lianyungang
PGT-A
1 trial -
PSMA PET/CT
The First People's Hospital of Lianyungang
Prostate Adenocarcinoma
1 trial -
PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy
The First People's Hospital of Lianyungang
Prostate Cancer Screening
1 trial -
Paclitaxel Oral Solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small-Cell Lung Cancer
1 trial -
Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
The First People's Hospital of Lianyungang
Breast Cancers
1 trial -
Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancers
1 trial -
Papillary epinephrine spraying
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatitis
1 trial -
Partially Hydrolyzed Whey Protein Formula
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Mild Allergic Symptoms in Infants
1 trial -
Peak value anti-Xa
The First People's Hospital of Lianyungang
Venous Thromboembolism
1 trial -
Peginterferon Ξ±-2b injection
The First People's Hospital of Lianyungang
Condylomata Acuminata
1 trial -
Peginterferon Ξ±-2b plus an anti-PD-1
The First People's Hospital of Lianyungang
Advanced Solid Tumors
1 trial -
Percutaneous transhepatic biliary stenting with conventional linear ^125^I seeds strand
The First People's Hospital of Lianyungang
Malignant Obstructive Jaundice
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources